Corneal Thinning During Topical Bevacizumab Therapy
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2007 by Yonsei University.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Yonsei University
Information provided by:
Yonsei University
ClinicalTrials.gov Identifier:
NCT00515684
First received: August 13, 2007
Last updated: NA
Last verified: August 2007
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.
| Condition | Intervention |
|---|---|
|
Corneal Neovascularization |
Drug: bevacizumab (Avastin) |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Basic Science |
Resource links provided by NLM:
Further study details as provided by Yonsei University:
Eligibility| Genders Eligible for Study: | Both |
Criteria
Inclusion Criteria:
- clinical diagnosis of corneal neovascularization
- must be able to apply eyedrop
Exclusion Criteria:
- have active keratitis
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00515684
Contacts
| Contact: Tae Im Kim, M.D. | 82-2-2228-3592 | tikim@yumc.yonsei.ac.kr |
Locations
| Korea, Republic of | |
| Severance hospital | Recruiting |
| Seoul, Korea, Republic of | |
| Contact: Tae Im Kim, M.D. 82-2-2228-3592 tikim@yumc.yonsei.ac.kr | |
Sponsors and Collaborators
Yonsei University
Investigators
| Principal Investigator: | Sang Woo Kim, M.D. | Severance hospital, Seoul , Korea |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00515684 History of Changes |
| Other Study ID Numbers: | 4-2006-0234 |
| Study First Received: | August 13, 2007 |
| Last Updated: | August 13, 2007 |
| Health Authority: | Korea: Institutional Review Board |
Additional relevant MeSH terms:
|
Neovascularization, Pathologic Corneal Neovascularization Metaplasia Pathologic Processes Corneal Diseases Eye Diseases Bevacizumab Angiogenesis Inhibitors |
Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Pharmacologic Actions Growth Inhibitors Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013